Corrigendum: Myelomodulatory Treatments Augment the Therapeutic Benefit of Oncolytic Viroimmunotherapy in Murine Models of Malignant Peripheral Nerve Sheath Tumors

Authors

• Siddhi N. Paudel, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Brian J. Hutzen, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Katherine E. Miller, Institute for Genomic Medicine, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Elizabeth A. Garfinkle, Institute for Genomic Medicine, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Chun-Yu Chen, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Pin-Yi Wang, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Andrea M. Glaspell, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Mark A. Currier, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Emily M. Ringwalt, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Louis Boon, JJP Biologics, Warsaw, Poland.
• Elaine R. Mardis, Institute for Genomic Medicine, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Mitchell S. Cairo, Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology, and Cell Biology, New York Medical College, Valhalla, NY, United States.Follow
• Nancy Ratner, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
• Rebecca D. Dodd, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States.
• Kevin A. Cassady, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
• Timothy P. Cripe, Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.

Author Type(s)

Faculty

DOI

10.3389/fimmu.2024.1456897

Journal Title

Frontiers in Immunology

First Page

1456897

Document Type

Article

Publication Date

1-1-2024

Department

Pediatrics

Keywords

T-VEC, immunotherapy, macrophage targeting, malignant peripheral nerve sheath tumors, oncolytic virotherapy, pexidartinib, trabectedin, tumor microenvironment

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1384623.].

Recommended Citation

Paudel, S. N., Hutzen, B. J., Miller, K. E., Garfinkle, E. A., Chen, C., Wang, P., Glaspell, A. M., Currier, M. A., Ringwalt, E. M., Boon, L., Mardis, E. R., Cairo, M. S., Ratner, N., Dodd, R. D., Cassady, K. A., & Cripe, T. P. (2024). Corrigendum: Myelomodulatory Treatments Augment the Therapeutic Benefit of Oncolytic Viroimmunotherapy in Murine Models of Malignant Peripheral Nerve Sheath Tumors. Frontiers in Immunology, 15, 1456897. https://doi.org/10.3389/fimmu.2024.1456897